These are Wall Street's most overbought stocks.
Some stocks could be in for a pullback as Wall Street wraps up a strong first half. The first half on Wall Street concludes after Friday's close . All three major indexes are on track to end the first half with gains, as investors have continued to ride the artificial intelligence boom despite worry over a lack of market breadth and an economic slowdown. The benchmark S & P 500 has gained roughly 15% in 2024, while the Dow Jones Industrial Average is up 5%.
Pro screened the S & P 500 for overbought names, based on their 14-day relative strength index. An RSI above 70 indicates overbought conditions for a stock, which could signal a downturn in the near term. A reading below 30 typically signals that a stock is oversold and could be due for gains. Shares of Microsoft registered a 14-day RSI reading of 74.
mountain Shares of Eli Lilly are also overbought, with a 14-day RSI of 83, putting the drug manufacturer at the top of the list. The stock has climbed nearly 57% in 2024. A large portion of Eli Lilly's rise in the first half of 2024 is thanks to the prominence of GLP-1 drugs , which emerged as a trend of its own for investors to pile into outside of the AI boom over the past year.
Markets Eli Lilly And Co Fedex Corp Walgreens Boots Alliance Inc Waters Corp Pool Corp Microsoft Corp S&P 500 Index Dow Jones Industrial Average NASDAQ Composite Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Read more »